JBM  Vol.7 No.2 , February 2019
Triple Effect of Doxorubicin, 5-Fluorouracil, Propranolol on Cell Survival on MCF-7 Breast Cancer Cell Line
Abstract: Purpose: Investigating the triple effect of doxorubicin, 5-fluorouracil, propranolol on MCF-7 (ER+, WTp53) breast cancer cell line with MTT test and survival analysis. Materials/Methods: In order to determine effective dosages of a combination of doxorubicin, 5-fluorouracil, propranolol on the MCF-7 cell line by using MTT and survival analysis technique. Result: IC50 values acquired by MTT tests are 0.01 mg/ml for doxorubicin, 6 mg/ml for 5-fluorouracil, 30 mg/ml for propranolol and 0.2/1/30 mg/ml (with previous respect) if all three agents are combined. It is found that the use of doxorubicin, 5-fluorouracil, and propranolol in combination is much effective than their single application. Discussion: Moderate concentrations of doxorubicin, 5-fluorouracil, and propranolol, if they are applied individually, showed high toxicity. When we used these drugs in combination; toxic effects lessened with respect to monotherapy. In the MCF-7 cell line, doxorubicin (IC50: 0.01 μM) increases cell death rates significantly and propranolol (IC50: 3 μM) has minimum effects in monotherapy in contrast to others. Propranolol is only superior to itself in combination therapy (IC50: 4 μM). However 5-fluorouracil (IC50: 30 μM) showed antagonistic effects with respect to other drugs. Additionally, having applied the three drugs in combination on the MCF-7 cell line for the first time in literature, it is highly possible to assess the application of doxorubicin, 5-fluorouracil and propranolol combination as a novel therapy option.
Cite this paper: Eroglu, O. , Kaya, H. , Celik, E. , Celen, M. , Korkut, E. and Nizam, N. (2019) Triple Effect of Doxorubicin, 5-Fluorouracil, Propranolol on Cell Survival on MCF-7 Breast Cancer Cell Line. Journal of Biosciences and Medicines, 7, 74-85. doi: 10.4236/jbm.2019.72007.

[1]   Amstutz, U., Froehlich, T.K. and Largiadèr, C. (2011) Dihydropyrimidine Dehydrogenase Gene as a Major Predictor of Severe 5-Fluorouracil Toxicity. Pharmacogenomic, 12, 1321-1336.

[2]   Eroglu, O. (2018) Investigation of Cytotoxic and Anti-Proliferative Effects of Betamethasone Valerate (BMV) on MDA-MB 231 Breast Cancer Cell Line. GMJ, 29, 331-335.

[3]   Ueda, K., Cardarelli, C., Gottesman, M.M. and Pastan, I. (1987) Expression of a Full-Length cDNA for the Human “MDR1” Gene Confers Resistance to Colchicine, Doxorubicin, and Vinblastine. Proceedings of National Academy of Sciences of USA, 84, 3004-3008.

[4]   Dai, X., Cheng, H., Bai, Z. and Jia, Li. (2017) Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. Journal of Cancer, 8, 3131-3141.

[5]   Trevor, A., Katzung, B. and Masters, S. (2012) Pharmacology: Examination and Board Review, Anthracycilne Antibiotics. McGraw Hill Medical Books, Pennsylvania Plaza New York City.

[6]   Fujiwara, A., Hoshino, T. and Westley, J. (1985) Anthracycline Antibiotics. Critical Reviews in Biotechnology, 3, 133-137.

[7]   McGowan, J.V., et al. (2017) Anthracycline Chemotherapy and Cardiotoxicity. Cardiovascular Drugs and Therapy, 31, 63-75.

[8]   Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C. and Spalla, C. (1969) Adriamycin, 14-Hydroxydaunomycin, a New Antitumor Antibiotic from S. Peucetius var. caesius. Biotechnology and Bioengineering, 11, 1101-1110.

[9]   Malla, S., Niraula, N.P., Singh, B., Liou, K. and Sohng, J.K. (2010) Limitations in Doksorubisin Production from Streptomyces peucetius. Microbiological Research, 165, 427-435.

[10]   Tacar, O., Sriamornsak, P. and Dass, C.R. (2013) Doxorubicin: An Update on Anticancer Molecular Action, Toxicity and Novel Drug Delivery Systems. The Journal of Pharmacy and Pharmacology, 65, 157-170.

[11]   Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., Van Tellingen, O., Janssen, J., Huijgens, P., Zwart, W. and Neefjes, J. (2013) Drug-Induced Histone Eviction from Open Chromatin Contributes to the Chemotherapeutic Effects of Doxorubicin. Nature Communications, 4, Article Number: 1908.

[12]   Pommier, Y., Leo, E., Zhang, H. and Marchand, C. (2010) DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs. Chemistry & Biology, 17, 421-433.

[13]   MInotti, G., et al. (2008) Anthracyclines. In: Offermanns, S. and Rosenthal, W., Eds., Encyclopedia of Molecular Pharmacology, Vol. 1, 2nd Edition, Springer, Berlin.

[14]   Momparler, R.L., Karon, M., Siegel, S.E. and Avila, F. (1976) Effect of Adriamycin on DNA, RNA, and Protein Synthesis in Cell-Free Systems and Intact Cells. Cancer Research, 36, 2891-2895.

[15]   Ha, J., Hwang, D., Yu, J., Park, D. and Ryu, H. (2011) Onset of Manic Episode during Chemotherapy with 5-Fluorouracil. Psychiatry Investigation, 8, 71-73.

[16]   Longley, B., Harkin, P. and Johnston, G. (2003) 5-Fluorouracil: Mechanisms of Action and Clinical Strategies. Nature Reviews Cancer, 3, 330-338.

[17]   Bankston, R. and Kass, R.S. (2010) Molecular Determinants of Local Anesthetic Action of Beta-Blocking Drugs: Implications for Therapeutic Management of Long QT Syndrome Variant 3. Journal of Molecular and Cellular Cardiology, 48, 246-253.

[18]   Wang, W., Mistry, M., Kahlig, M., Kearney, A., Xiang, J. and George, L. (2010) Propranolol Blocks Cardiac and Neuronal Voltage-Gated Sodium Channels. Frontiers in Pharmacology, 1, 144.

[19]   Desaphy, J.F., Pierno, S., De Luca, A., Didonna, P. and Camerino, D.C. (2003) Different Ability of Clenbuterol and Salbutamol to Block Sodium Channels Predicts Their Therapeutic Use in Muscle Excitability Disorders. Molecular Pharmacology, 63, 659-670.

[20]   Thorn, C.F, Oshiro, C., Marsh, S., Boussard, T.H., McLeod, H., Klein, T.E., Russ, B. and Altman, R.B. (2011) Doxorubicin Pathways: Pharmacodynamics and Adverse Effects. Pharmacogenet Genomics, 21, 440-446.

[21]   van Kuilenburg, A.B.P., Hausler, P., Schalhorn, A., Tanck, M.W.T., Proost, J.H., Terborg, C. and Maring, J.G. (2012) Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a c.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy. Clinical Pharmacokinetics, 51, 163-174.

[22]   Etienne, M.C., Milano, G., Renée, N., Lagrange, J.L., Dassonville, O., Thyss, A. and Demard, F. (1195) Population Study of Dihydropyrimidine Dehydrogenase in Cancer Patients. Bulletin Du Cancer, 82, 705-710.

[23]   Borràs, E., Doto, E., Arcusa, A., Gamundi, M.J., Herna, I., Dias, M. and Carballo, M. (2012) High-Resolution Melting Analysis of the Common c.1905+1G>A Mutation Causing Dihydropyrimidine Dehydrogenase Deficiency and Lethal 5-Fluorouracil Toxicity. Frontiers in Genetics, 3, 312-312.

[24]   Kuilenburg, A.B., Muller, E.W., Haasjes, J., Meinsma, R., Zoetekouw, L., Waterham, H.R. and Gennip, A.H. (2001) Lethal Outcome of a Patient with a Complete Dihydropyrimidine Dehydrogenase (DPD) Deficiency after Administration of 5-Fluorouracil: Frequency of the Common IVS14 + 1G > A Mutation Causing DPD Deficiency. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 7, 1149-1153

[25]   Latchman, J., Guastella, A.M. and Tofthagen, C. (2014) 5-Fluorouracil Toxicity and Dihydropyrimidine Dehydrogenase Enzyme: Implications for Practice. Clinical Journal of Oncology Nursing, 18, 581-585.

[26]   Pantziarka, P., Bouche, G., Sukhatme, V., Meheus, L., Rooman, I. and Sukhatme, V.P. (2016) Repurposing Drugs in Oncology (ReDO)—Propranolol as an Anti-Cancer Agent. Ecancermedicalscience, 10, 680.

[27]   Rastegar, H., Ahmadi, H., Anjarani, S., et al. (2013) The Role of Milk Thistle Extract in Breast Carcinoma Cell Line (MCF-7) Apoptosis with Doksorubisin. Acta Medica Iranica, 51, 591-598.

[28]   Zoli, W., Ulivi, P., Tesei, A., Fabbri, F., Rosetti, M., Maltoni, R., Giunchi, D.C., Luca, L., Brigliadori, G., Vannini, I. and Amadori, D. (2005) Addition of 5-Fluorouracil to Doxorubicin-Paclitaxel Sequence Increases Caspase-Dependent Apoptosis in Breast Cancer Cell Lines. Breast Cancer Research, 7, R681-R689.

[29]   Kugawa, F., Ueno, A., Kawasaki, M. and Aoki, M. (2004) Evaluation of Cell Death Caused by CDF (Cyclophosphamide, Doxorubicin, 5-Fluorouracil) Multi-Drug Administration in the Human Breast Cancer Cell Line MCF-7. Biological and Pharmaceutical Bulletin, 27, 392-398.

[30]   Pasquier, E., Ciccolini, J., Carre, M., Giacometti, S., Fanciullino, R., Pouchy, C., Montero, M.P., Serdjebi, C., Kavallaris, M. and André, N. (2011) Propranolol Potentiates the Anti-Angiogenic Effects and Anti-tumor Efficacy of Chemotherapy Agents: Implication in Breast Cancer Treatment. Oncotarget, 2, 797-809.

[31]   Thaker, P.H., Han, L.Y., Kamat, A.A., Arevalo, J.M., Takahashi, R., Lu, C., Jennings, N.B., Armaiz-Pena, G., Bankson, J.A., Ravoori, M., Merritt, W.M., Lin, Y.G., Mangala, L.S., Kim, T.J., Coleman, R.L., Landen, C.N., et al. (2006) Chronic Stress Promotes Tumor Growth and Angiogenesis in a Mouse Model of Ovarian Carcinoma. Nature Medicine, 12, 939-944.

[32]   Sloan, E.K., Priceman, S.J., Cox, B.F., Yu, S., Pimentel, M.A., Tangkanangnukul, V., Arevalo, J.M., Morizono, K., Karanikolas, B.D., Wu, L., Sood, A.K. and Cole, S.W. (2010) The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer. Cancer Research, 70, 7042-7052.

[33]   Schuller, H.M. (2010) Beta-Adrenergic Signaling, a Novel Target for Cancer Therapy? Oncotarge, 1, 466-469.

[34]   Soule, H.D., Vazquez, J., Long, A., Albert, S. and Brennan, M. (1973) A Human Cell Line from a Pleural Effusion Derived from a Breast Carcinoma. Journal of the National Cancer Institute, 51, 1409-1416.

[35]   Ashburn, T.T. and Thor, K.B. (2004) Drug Repositioning: Identifying and Developing New Uses for Existing Drugs. Nature Reviews Drug Discovery, 3, 673-683.

[36]   O’Connor, K.A. and Roth, B.L. (2005) Finding New Tricks for Old Drugs: An Efficient Route for Public-Sector Drug Discovery. Nature Reviews Drug Discovery, 4, 1005-1014.

[37]   Martin, H., Smith, L. and Tomlinson, D. (2014) Multidrug-Resistant Breast Cancer: Current Perspectives. Breast Cancer: Targets and Therapy, 6, 1-13.